TABLE 2. Common clinical effects associated with tianeptine exposures (N = 114) and therapies received — National Poison Data System, United States, 2000–2017.
| Clinical effect* | No. | (%) |
|---|---|---|
|
Cardiovascular effect
|
37
|
(32.5)
|
| Tachycardia |
29 |
(25.4) |
| High blood pressure |
13 |
(11.4) |
| Conduction delays |
5 |
(4.4) |
|
Neurologic effect
|
55
|
(48.3)
|
| Agitation |
25 |
(21.9) |
| Drowsiness |
19 |
(16.7) |
| Confusion |
15 |
(13.2) |
| Coma |
5 |
(4.4) |
|
Gastrointestinal effect
|
12
|
(10.5)
|
| Nausea |
9 |
(7.9) |
| Vomiting |
5 |
(4.4) |
| Diarrhea |
3 |
(2.6) |
|
Dermal effect
|
10
|
(8.8)
|
| Pallor |
3 |
(2.6) |
| Pain |
3 |
(2.6) |
| Cellulitis |
2 |
(1.8) |
|
Constitutional effect
|
10
|
(8.8)
|
| Diaphoresis |
8 |
(7.0) |
| Fever |
3 |
(2.6) |
| Pain |
1 |
(0.9) |
|
Respiratory effect
|
8
|
(7.0)
|
| Respiratory depression |
6 |
(5.3) |
| Dyspnea |
3 |
(2.6) |
| Tachypnea |
1 |
(0.9) |
|
Ocular effect
|
6
|
(5.3)
|
| Mydriasis |
4 |
(3.5) |
| Miosis |
2 |
(1.8) |
|
Renal effect
|
5
|
(4.4)
|
| Urinary retention |
3 |
(2.6) |
| Creatinine abnormality |
2 |
(1.8) |
| Kidney failure |
1 |
(0.9) |
|
Metabolic effect
|
5
|
(4.4)
|
| Electrolyte disturbances |
3 |
(2.6) |
| Acidosis |
2 |
(1.8) |
|
Musculoskeletal effect
|
5
|
(4.4)
|
| Muscle weakness |
2 |
(1.8) |
| Rigidity |
1 |
(0.9) |
|
Psychiatric effect
|
2
|
(1.8)
|
| Delusions |
2 |
(1.8) |
|
Therapy
| ||
| Fluids |
40 |
(35.1) |
| Benzodiazepines |
31 |
(27.2) |
| Oxygen |
12 |
(10.5) |
| Naloxone |
11 |
(9.7) |
| Antibiotics |
11 |
(9.7) |
| Sedation |
9 |
(7.9) |
| Antiemetics |
7 |
(6.1) |
| Intubation |
5 |
(4.4) |
| Ventilator support |
5 |
(4.4) |
| Antihistamine | 3 | (2.6) |
* Patient exhibited one or more type of clinical effect in a category.